Specificity of adoptive chemoimmunotherapy of established syngeneic tumors
- PMID: 6156213
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors
Abstract
To examine the specificity of adoptive chemoimmunotherapy (ACIT) of established syngeneic tumors, two noncross-reactive C57BL/6 tumors were studied: a Friend virus-induced tumor (FBL-3) and a chemically induced virus-negative tumor EL-4(G-). In vitro studies confirmed that these tumors are antigenically distinct by demonstrating that the cytotoxic responses of spleen cells from mice immunized in vivo and reexposed to tumor in vitro are immunologically specific. Studies of ACIT with cells from mice immunized in vivo demonstrated similar specificity. Mice receiving 5 x 10(6) FBL-3 on day 0 all died by day 13. Treatment on day 5 with cyclophosphamide (CY), 180 mg/kg, prolonged the median survival time (MST) to day 23. Treatment on day 5 with CY plus 2 x 10(7) normal nonimmune C57BL/6 cells or CY plus cells sensitized to EL-4(G-) had no additional effect on survival whereas 2 x 10(7) C57BL/6 cells sensitized to FBL-3 in vivo prolonged MST to day 64 and cured 13 of 32 mice. Similarly, mice given 2 x 10(5) EL-4(G-) on day 0 all died by day 16, and CY on day 5 prolonged the MST to day 22. As an adjunct to CY, 2 X 10(7) normal cells or cells sensitized to FBL-3 had a modest effect, prolonging the MST to days 37 and 36, respectively. However, treatment with CY plus 2 x 10(7) cells immune to EL-4(G-) cured 22 of 32 mice. The results demonstrate the immunologic specificity of ACIT of syngeneic tumors treated with immune syngeneic cells.
Similar articles
-
Therapy of leukemia by nonimmune syngeneic spleen cells.J Immunol. 1980 May;124(5):2137-42. J Immunol. 1980. PMID: 7365249
-
Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.J Immunol. 1975 Jul;115(1):234-8. J Immunol. 1975. PMID: 1080165
-
Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.Cancer Res. 1981 Jul;41(7):2658-63. Cancer Res. 1981. PMID: 7018668
-
Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.J Natl Cancer Inst. 1982 Jul;69(1):109-16. J Natl Cancer Inst. 1982. PMID: 6980314
-
Specific adoptive immunotherapy: experimental basis and future potential.Surv Immunol Res. 1982;1(1):85-90. doi: 10.1007/BF02918244. Surv Immunol Res. 1982. PMID: 6764836 Review. No abstract available.
Cited by
-
Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.Clin Cancer Res. 2019 Jan 1;25(1):358-368. doi: 10.1158/1078-0432.CCR-18-1211. Epub 2018 Nov 13. Clin Cancer Res. 2019. PMID: 30425092 Free PMC article.
-
Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo.J Exp Med. 1994 Jan 1;179(1):31-42. doi: 10.1084/jem.179.1.31. J Exp Med. 1994. PMID: 8270874 Free PMC article.
-
Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients.Oncol Lett. 2017 Sep;14(3):3379-3386. doi: 10.3892/ol.2017.6635. Epub 2017 Jul 20. Oncol Lett. 2017. PMID: 28927091 Free PMC article.
-
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.J Clin Oncol. 2005 Apr 1;23(10):2346-57. doi: 10.1200/JCO.2005.00.240. J Clin Oncol. 2005. PMID: 15800326 Free PMC article. Clinical Trial.
-
Therapeutic cancer vaccines: are we there yet?Immunol Rev. 2011 Jan;239(1):27-44. doi: 10.1111/j.1600-065X.2010.00979.x. Immunol Rev. 2011. PMID: 21198663 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials